29 Jan 2019
Import Controls Continued on Synthetic Cannabinoid
The U.S. Drug Enforcement Administration has issued a final rule that, effective 29 January, places the synthetic cannabinoid N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H- indazole-3-carboxamide (MABCHMINACA; ADB-CHMINACA), including its salts, isomers and salts of isomers whenever the existence of such is possible, into schedule I of the Controlled Substances Act.
This substance was previously placed into schedule I temporarily; as a result, this rule permanently continues the regulatory controls and administrative, civil and criminal sanctions applicable to schedule I controlled substances on persons who handle (import, export, manufacture, distribute, engage in research, conduct instructional activities or chemical analysis, or possess) this substance. These include the following.
- all importation and exportation of this substance must be in compliance with 21 USC 952, 953, 957 and 958 and in accordance with 21 CFR part 1312
- any activity involving this substance that is not authorised by, or is in violation of, the Controlled Substances Act or its implementing regulations is unlawful and may subject the person to administrative, civil or criminal sanctions
- any person who handles or desires to handle this substance must be registered with the DEA to conduct such activities
- all labels and labelling for commercial containers of this substance must comply with 21 USC 825 and 958(e) and be in accordance with 21 CFR part 1302
- only registered manufacturers are permitted to manufacture this substance in accordance with an assigned quota
- every DEA registrant that possesses any quantity of substance must take an inventory of all stocks on hand as of 29 January